Healthcare Industry News: Mylan Laboratories
News Release - March 23, 2007
Pfizer Announces Launch of Generic Amlodipine Besylate Product by GreenstoneNEW YORK--(HSMN NewsFeed)--In response to an announcement today by Mylan Laboratories that it has launched a generic competitor to Norvasc, Pfizer said it is making available its own generic amlodipine besylate product immediately through the company's Greenstone subsidiary. Norvasc also will remain available to patients.
Pfizer said it will continue to pursue all available legal remedies to protect the market for Norvasc through a six-month pediatric exclusivity period that expires in September, 2007.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsREGENXBIO Announces New License Agreement with Pfizer for the Treatment of Friedreich's Ataxia Using NAV(R) AAV9 Vector
Mylan and Upjohn, a Division of Pfizer, to Combine, Creating a New Champion for Global Health Uniquely Positioned to Fulfill the World's Need for Medicine
Statement from Mylan's Board of Directors Regarding Retirement of CEO and Board Member Heather Bresch in Conjunction with the Combination of Mylan and Upjohn, a Division of Pfizer